Bachurski, P.; Chmiel, G.; Kalinowski, P.; Międlar, M.; Muda, M.; Pacek, S.; Pierzga, E.; Wiśniewski, K.; Witkowski, P.; Zarański, B. Optimal First-Line Use of Pembrolizumab in Metastatic Driver-Negative NSCLC: Monotherapy Versus Chemo-Immunotherapy (Evidence 2022–2025). Qual Sport 2026, 51, 68252.